Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright

Xeris Biopharma (NASDAQ:XERS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 68.35% from the company’s previous close.

Several other research analysts also recently weighed in on XERS. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, January 21st. Oppenheimer reiterated an “outperform” rating and set a $18.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Barclays initiated coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Finally, Piper Sandler boosted their price target on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.08.

Xeris Biopharma Stock Performance

XERS stock opened at $5.94 on Monday. The stock’s 50 day moving average price is $7.18 and its 200 day moving average price is $7.62. The firm has a market cap of $985.56 million, a P/E ratio of -593.41 and a beta of 0.61. Xeris Biopharma has a 1 year low of $3.59 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 3.01% and a net margin of 0.19%.The company had revenue of $85.81 million during the quarter, compared to analysts’ expectations of $86.00 million. On average, research analysts predict that Xeris Biopharma will post -0.41 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $7.43, for a total transaction of $123,835.81. Following the completion of the sale, the insider directly owned 1,308,103 shares of the company’s stock, valued at $9,719,205.29. The trade was a 1.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $7.09, for a total value of $106,350.00. Following the completion of the transaction, the director directly owned 142,500 shares in the company, valued at $1,010,325. This trade represents a 9.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 223,641 shares of company stock worth $1,628,285 over the last 90 days. Company insiders own 4.56% of the company’s stock.

Institutional Trading of Xeris Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of XERS. Calamos Advisors LLC acquired a new position in Xeris Biopharma in the 3rd quarter worth $1,116,000. Voya Investment Management LLC increased its position in shares of Xeris Biopharma by 866.6% during the third quarter. Voya Investment Management LLC now owns 400,079 shares of the company’s stock worth $3,257,000 after acquiring an additional 358,689 shares during the last quarter. Squarepoint Ops LLC increased its position in shares of Xeris Biopharma by 1,679.1% during the second quarter. Squarepoint Ops LLC now owns 284,567 shares of the company’s stock worth $1,329,000 after acquiring an additional 268,572 shares during the last quarter. Savvy Advisors Inc. acquired a new position in shares of Xeris Biopharma in the second quarter worth about $189,000. Finally, Corient Private Wealth LLC purchased a new position in Xeris Biopharma in the second quarter valued at about $320,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Key Headlines Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 results: Xeris reported EPS of $0.0615 vs. $0.03 expected and FY2025/quarterly revenue roughly in line at $85.8M, which helped drive an immediate post‑earnings lift. Read More.
• Positive Sentiment: Raised FY‑2026 revenue outlook and growth targets: Management guided revenue of $375–$390M for FY2026 (consensus ~ $370.3M) and is targeting >30% revenue growth next year while investing more behind Recorlev and advancing XP‑8121 — a growth story that underpins the bullish case. Read More.
• Positive Sentiment: Analyst support: HC Wainwright reaffirmed a Buy and set a $10 price target, signaling institutional conviction in Xeris’ growth path. Read More.
• Neutral Sentiment: Full earnings commentary and transcripts are available for investors wanting details on margins, channel dynamics and product-level performance. (Useful for modeling but not a binary catalyst.) Read More.
• Negative Sentiment: Recorlev exclusivity/patent risk: Coverage highlights active patent battles around Recorlev; losing exclusivity or adverse rulings could materially affect future sales and justify investor caution despite current profitability gains. This legal overhang appears to be the main reason traders trimmed positions today. Read More.
• Negative Sentiment: Revenue nuance and reinvestment: Quarterly revenue was just shy of some estimates ($85.8M vs. ~$86M) and management is increasing investment behind Recorlev and pipeline assets — a tradeoff that can pressure near‑term margins and leave execution risk. Read More.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.